Vismodegib

BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

July 2017

Comments

DO NOT PRESCRIBE (DNP)6: NICE TA489 - vismodegib for treating basal cell carcinoma. (Decision date - December 2017)

RED1,2,3:  For the treatment of adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas. (Decision date - December 2021)

NHS England drug - to be used in line with NHS England commissioning intentions.

 

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again